Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN2220 in adults with transthyretin amyloid cardiomyopathy
NL-OMON59286Phase 3Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in amyloidotic transthyretin cardiomyopathy (ATTR-CM) comparing ALXN2220 with Placebo (2 arms). Primary endpoint: Total occurrence of all-cause mortality and cardiovascular clinical events during the blinded treatment period. Started Aug 2024; status: active, not recruiting.
02
Drugs
cliramitug
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NL-OMON59286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59286.